🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very pleased to announce my first book, entitled “Equal Care: Health Equity, Social Democracy, and the Egalitarian State” will be out in early 2024. Will update as more info and pre-order link becomes available. ncbi.nlm.nih.gov/nlmcatalog/477…

Drs. Dallas Mindo-Panusis, Rebecca Sudore Rebecca Sudore, Irena Cenzer, Alex Smith, MD, and @AshwinKotwalMD published a paper entitled "Disparities in advance care planning among older US immigrants" in JAGS. agsjournals.onlinelibrary.wiley.com/doi/10.1111/jg… #geriatrics #ucsf UC San Francisco

Editorial: "Ultimately, new treatments such as donanemab will not only change the Alzheimer research landscape but also the clinical one." ja.ma/3XRM91i Eric Widera, MD Sharon Brangman Nathaniel Chin #AAIC23

The TRAILBLAZER-ALZ 2 study published on Donanemab for #Alzheimer’s disease was just published in JAMA. I had the honor to write the editorial along with Nathaniel Chin and Sharon Brangman. Here is a thread summarizing my thoughts. #EndAlz #AAIC23 jamanetwork.com/journals/jama/… 🧵1/20

📢Excited to announce EchoCLIP, or vision-language foundation #AI model for #echofirst interpretation. Using over 1,000,000 cardiac ultrasound videos paired with expert cardiologist interpretations, we enable #echofirst semantic search and zero-shot predictions. EchoCLIP can

In our JAMA Viewpoint article, Sachin J. Shah, Alvaro Pascual-Leone, and I discuss the safety risk of using antiamyloid mAbs for treatment of mild cognitive impairment or early dementia in patients who may require anticoagulation or thrombolytic therapy.

As Sachin J. Shah eloquently stated in the article, "Cerebral amyloid angiopathy and apolipoprotein ε4 homozygosity are discernable, fixed risk factors, but antithrombotic use is considerably more dynamic." For the interested audience: jamanetwork.com/journals/jama/…

This JAMA Guide to Statistics and Methods article explains effect score analyses, an approach for evaluating the heterogeneity of treatment effects, and examines its use in a study of oxygen-saturation targets in critically ill patients. ja.ma/49VuafK #ISICEM24

I found a nice paper Sachin J. Shah et al, re *net* benefits from oral AC in AF based on competing risks As competing risks increase OAC benefit decreases. As life expectancy decreases, benefit also decreases CHADSVASC is too simple Do read the paper in Circ: CQO

Fascinating study on LLMs and diagnostic reasoning

Anticoagulants for AF detected without symptoms is tricky. Finding the right patient population to treat is key. I shared my take on a subgroup analysis of the ARTESIA trial in a JACC Journals editorial out today sciencedirect.com/science/articl…

Why Do We (and Still Do!) Need the National Institute on Aging jamanetwork.com/journals/jamai…

One of our fantastic Harvard GIM fellows! Great work by Emily. Worth a listen.

Screen for the level of #frailty when assessing #antihypertensive therapy #ESCCongress New guidelines on #hypertension European Society of Cardiology PCRonline 🫀 European Society of Cardiology Journals rafavidalperez MIЯVΛƬ #IC Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Ritu Thamman MD Silvia Castelletti

#ResearchMinute Check out this State of the Art BMJ Review by CASI faculty Sachin J. Shah on Atrial Fibrillation Management in Older Adults! bmj.com/content/386/bm… #atrialfibrillation #olderadults #agingcare #hearthealth #AFib #chronicillness

We are in a unique moment with new treatments for Alzheimer's disease. There is lots of promise but the potential to make the same mistakes that we've made in the past. Naveen Reddy MD and I put together some of our thoughts on how to get this right.